other material
confidence high
sentiment positive
materiality 0.90
Avalo Therapeutics Phase 2 LOTUS trial meets primary endpoint; HiSCR75 rates 42.2% and 42.9% for abdakibart in HS
Avalo Therapeutics, Inc.
- Abdakibart 150 mg achieved 42.2% HiSCR75 (p=0.018), 300 mg achieved 42.9% (p=0.015); placebo 25.6%.
- Statistically significant benefit on secondary endpoints HiSCR50, change in IHS4, and draining tunnel count.
- Abdakibart well tolerated; most TEAEs mild to moderate, no neutropenia, serious infections, or opportunistic infections.
- Response similar in patients with and without prior biologic exposure.
- Avalo plans to advance abdakibart into a registrational Phase 3 program.